These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 6284474)
41. [Detoxication in opiate addiction and prevention of recurrence: administration of naltrexone and cognitive behavior therapy]. Roozen HG; Deden AL; Kerkhof AJ; Vorsteveld JP; van den Brink W Ned Tijdschr Geneeskd; 1997 Dec; 141(49):2377-80. PubMed ID: 9554156 [TBL] [Abstract][Full Text] [Related]
42. Recent advances in opiate detoxification: clonidine and lofexidine. Washton AM; Resnick RB NIDA Res Monogr; 1983 Apr; 43():44-50. PubMed ID: 6410276 [No Abstract] [Full Text] [Related]
46. [Clonidine for the treatment of heroin withdrawal syndrome]. Schanda H; Presslich O; Hermann P Wien Klin Wochenschr; 1983 Aug; 95(16):569-72. PubMed ID: 6649643 [TBL] [Abstract][Full Text] [Related]
48. [Changes in alpha 2-adrenoceptor binding nature in guinea-pig brain following the development of morphine dependence]. Ohta S; Niwa M; Nozaki M; Asano T; Takeda T; Dohi S Masui; 1997 May; 46(5):640-3. PubMed ID: 9185461 [TBL] [Abstract][Full Text] [Related]
49. Pharmacologic interventions for the treatment of opioid dependence and withdrawal. Guthrie SK DICP; 1990; 24(7-8):721-34. PubMed ID: 2197814 [TBL] [Abstract][Full Text] [Related]
50. Clonidine in acute opiate withdrawal. Gold MS; Pottash AL; Extein I; Kleber HD N Engl J Med; 1980 Jun; 302(25):1421-2. PubMed ID: 7374703 [No Abstract] [Full Text] [Related]
51. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857 [TBL] [Abstract][Full Text] [Related]
52. [Use of clonidine in the treatment of morphine withdrawal syndrome: neuropharmacological bases and clinical application]. Gurpegui M; Sweeney DR; Gold MS Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1983; 11(3):253-8. PubMed ID: 6687343 [No Abstract] [Full Text] [Related]
54. Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Honey BL; Benefield RJ; Miller JL; Johnson PN Ann Pharmacother; 2009 Sep; 43(9):1506-11. PubMed ID: 19690220 [TBL] [Abstract][Full Text] [Related]
55. [Intrahospital treatment of acute opiate withdrawal syndrome using the non-opiate agent clonidine]. Cerdeño V; Pintado R; García de Lorenzo A; Galván B; Aguado A Med Clin (Barc); 1983 Oct; 81(11):472-4. PubMed ID: 6656347 [No Abstract] [Full Text] [Related]
56. Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study. Uhde TW; Redmond DE; Kleber HD Psychiatry Res; 1980 Mar; 2(1):37-47. PubMed ID: 6932053 [TBL] [Abstract][Full Text] [Related]
57. Clonidine for opiate withdrawal. Med Lett Drugs Ther; 1979 Nov; 21(24):100. PubMed ID: 502968 [No Abstract] [Full Text] [Related]
58. Clonidine in opiate withdrawal: review and appraisal of clinical findings. Washton AM; Resnick RB Pharmacotherapy; 1981; 1(2):140-6. PubMed ID: 6765486 [TBL] [Abstract][Full Text] [Related]
59. [Clonidine in opiate abstinence]. Maurset A; Bratfors O Tidsskr Nor Laegeforen; 1979 May; 99(15):791-2. PubMed ID: 462445 [No Abstract] [Full Text] [Related]
60. Guanabenz acetate: a new, long-acting alpha-two adrenergic agonist for opioid withdrawal. Tennant FS; Rawson RA NIDA Res Monogr; 1984 Mar; 49():338-43. PubMed ID: 6090917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]